Document:

Exhibit
10.1

 

SERIES
A PREFERRED STOCK PURCHASE AGREEMENT

 

THIS
SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 18th day of June,
2020 by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the investors listed
on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”).

 

The
parties hereby agree as follows:

 

1.
Purchase and Sale of Preferred Stock.

 

1.1
Sale and Issuance of Preferred Stock.

 

(a)
The Company shall adopt and file with the Secretary of State of the State of Delaware on or before the Initial Closing (as defined
below) the Amended and Restated Certificate of Incorporation in the form of Exhibit B attached to this Agreement (the “Restated
Certificate”).

 

(b)
Subject to the terms and conditions of this Agreement, each Purchaser agrees to purchase at the Closing and the Company agrees
to sell and issue to each Purchaser at the Closing that number of shares of Series A Preferred Stock, $0.0001 par value per share
(the “Series A Preferred Stock”), set forth opposite each Purchaser’s name on Exhibit A, at a
purchase price of $8.79120 per share. The shares of Series A Preferred Stock issued to the Purchasers pursuant to this Agreement
(including any shares issued at the Initial Closing and any Milestone Shares, as defined below) shall be referred to in this Agreement
as the “Shares.”

 

1.2
Closing; Delivery.

 

(a)
The initial purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures, at such time
and place as the Company and the Purchasers mutually agree upon, orally or in writing (which time and place are designated as
the “Initial Closing”). In the event there is more than one closing, the term “Closing”
shall apply to each such closing unless otherwise specified.

 

(b)
At each Closing, the Company shall deliver to each Purchaser a certificate representing the Shares being purchased by such Purchaser
at such Closing against payment of the purchase price therefor by check payable to the Company, by wire transfer to a bank account
designated by the Company.

 

1.3
Sale of Milestone Warrants to Purchase Shares of Preferred Stock.

 

(a)
After the Initial Closing, the Company shall sell, and the Purchasers shall purchase, on the terms and conditions set forth in
that certain Warrant Purchase Agreement attached hereto as Exhibit J (“Warrant Purchase Agreement”),
warrants to purchase up to 1,149,401 additional shares of Series A Preferred Stock (the “Milestone Warrants”),
as set forth on Exhibit A hereto, on the certification by the Board that the events specified in Exhibit I attached
to this Agreement have occurred (the “Milestone Events”). The date of the purchase and sale of the Milestone
Warrants is referred to in this Agreement as the “Milestone Closing.” Notwithstanding the foregoing, any Purchaser
may, in such Purchaser’s discretion, elect to consummate a Milestone Closing in respect of such Purchaser’s portion
of the Milestone Warrants at any time prior to the occurrence of the Milestone Events. A Purchaser shall be entitled to assign
the obligation to purchase Milestone Warrants under this Section 1.3(a) to (i) its Affiliates and (ii) its beneficial interest
holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined
in Rule 13d-3 promulgated under the Exchange Act, of such Purchaser (“Purchaser Beneficial Owners”); provided
that each such Affiliate or Purchaser Beneficial Owner (x) is not a Competitor or FOIA Party (as such terms are defined in
the Investors’ Rights Agreement and as determined in the discretion of the Board of Directors of the Company (“Board”)),
unless such party’s purchase of Milestone Warrants is otherwise consented to by the Board, (y) agrees to enter into the
Warrant Purchase Agreement, and (z) agrees to purchase at least twenty-five (25%) of the Milestone Warrants obligated to be purchased
by such Purchaser at the Milestone Closing.

 

    	 

    	 

    

 

(b)
At the Milestone Closing, if any Purchaser or any Affiliate of such Purchaser (other than any Affiliate that has a direct obligation
to purchase Milestone Warrants) fails to purchase the Milestone Warrants that such Person is obligated to purchase pursuant to
Subsection 1.3(c) hereof or any other agreement between such Person and the Company (a “Defaulting Purchaser”),
then each share of Series A Preferred Stock held immediately prior to the Milestone Closing by such Milestone Closing Defaulting
Purchaser or any of its Affiliates (other than any Affiliate that has a direct obligation to purchase Milestone Warrants) shall
automatically and without further action on the part of such Milestone Defaulting Purchaser or any of its Affiliates (other than
any Affiliate that has a direct obligation to purchase Milestone Warrants) be converted, effective upon, and subject to and concurrently
with the consummation of the Milestone Closing, into fully-paid and non-assessable shares of Common Stock at the rate of (1) share
of Series A Preferred Stock to one (1) share of Common Stock, all pursuant to, and as further provided in, Section 5A.1 of Part
B Article Fourth of the Restated Certificate (a “Special Mandatory Conversion).

 

(c)
Each Purchaser that has complied with its obligations to purchase Milestone Warrants (each, a “Complying Purchaser”)
as of such date and has not been subject to a “Special Mandatory Conversion” shall have an option (and the Company
shall notify each such Purchaser of such option), exercisable by delivering written notice to the Company within fifteen days
after receipt of the Company’s notice regarding the Defaulting Purchaser, to purchase, and the Company shall sell to such
Purchaser, up to its pro rata percentage (based on the number of shares of Common Stock issued or issuable upon conversion of
Shares held by held by such Complying Purchaser compared to the total number of shares of Common Stock issued or issuable upon
conversion of Shares held by held by all Complying Purchasers) of the Milestone Warrants that the Defaulting Purchaser failed
to purchase (such warrants being referred to herein as “Optional Warrants”, and each Complying Purchaser electing
to purchase being referred to herein as a “Participating Purchaser”), which notice shall also indicate the
maximum number of Milestone Warrants, if any, such Participating Purchaser would purchase in excess of such Participating Purchaser’s
pro rata percentage (the “Excess Amount”). If one or more such Complying Purchaser declines to exercise its
option to purchase Optional Warrants, or elects to purchase less than such Complying Purchaser’s pro rata percentage of
the Optional Warrants, then such rejected Milestone Warrants shall automatically be deemed to be accepted by the Participating
Purchasers who specified an Excess Amount in their respective notices delivered to the Company, allocated among such Participating
Purchasers in proportion to their respective pro rata percentages; provided, that in no event shall an amount greater than a Participating
Purchaser’s Excess Amount be allocated to such Participating Purchaser. The procedure set forth in the preceding sentence
shall be employed on an iterative basis until the entire Excess Amount of each Participating Purchaser has been satisfied or until
all of the Optional Warrants shall have been allocated.

 

1.4 Use
of Proceeds. In accordance with the directions of the Company’s Board of Directors, as it shall be constituted in
accordance with the Voting Agreement, the Company will use the proceeds from the sale of the Shares for product development
and other general corporate purposes.

 

    	2

    	 

    

 

1.5 Defined
Terms Used in this Agreement. In addition to the terms defined above, the following terms used in this Agreement shall be
construed to have the meanings set forth or referenced below.

 

(a)
“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls,
is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member,
officer, director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter existing
that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management
company or investment adviser with, such Person.

 

(b)
“Code” means the Internal Revenue Code of 1986, as amended.

 

(c)
“Company Intellectual Property” means all patents, patent applications, registered and unregistered trademarks,
trademark applications, registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets,
domain names, mask works, information and proprietary rights and processes, similar or other intellectual property rights, subject
matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing,
and any and all such cases that are owned or used by the Company in the conduct of the Company’s business as now conducted
and as presently proposed to be conducted.

 

(d)
“Indemnification Agreement” means the agreement between the Company and the director and Purchaser Affiliates
designated by any Purchaser entitled to designate a member of the Board of Directors pursuant to the Voting Agreement, dated as
of the date of the Initial Closing, in the form of Exhibit D attached to this Agreement.

 

(e)
“Investors’ Rights Agreement” means the agreement among the Company and the Purchasers dated as of the
date of the Initial Closing, in the form of Exhibit E attached to this Agreement.

 

(f)
“Key Employee” means any executive-level employee (including division director and vice president-level positions)
as well as any employee or consultant who either alone or in concert with others develops, invents, programs or designs any Company
Intellectual Property.

 

(g)
“Knowledge” including the phrase “to the Company’s knowledge” shall mean the actual
knowledge of Jonathan F. Lawler.

 

(h)
“Management Rights Letter” means the agreement between the Company and 22NW, LP, dated as of the date of the
Initial Closing, in the form of Exhibit F attached to this Agreement.

 

(i)
“Material Adverse Effect” means a material adverse effect on the business, assets (including intangible assets),
liabilities, financial condition, property or results of operations of the Company.

 

(j)
“Person” means any individual, corporation, partnership, trust, limited liability company, association or other
entity.

 

(k)
“Purchaser” means each of the Purchasers who is initially a party to this Agreement and any Additional Purchaser
who becomes a party to this Agreement at a subsequent Closing under Subsection 1.2(b).

 

    	3

    	 

    

 

(l)
“Right of First Refusal and Co-Sale Agreement” means the agreement among the Company, the Purchasers, and certain
other stockholders of the Company, dated as of the date of the Initial Closing, in the form of Exhibit G attached to this
Agreement.

 

(m)
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

(n)
“Shares” means the shares of Series A Preferred Stock issued at the Initial Closing and any Milestone Shares
for which a Milestone Warrant is issued at a subsequent Closing under Subsection 1.2(b).

 

(o)
“Transaction Agreements” means this Agreement, the Investors’ Rights Agreement, the Management Rights
Letter, the Right of First Refusal and Co-Sale Agreement, the Voting Agreement.

 

(p)
“Voting Agreement” means the agreement among the Company, the Purchasers and certain other stockholders of
the Company, dated as of the date of the Initial Closing, in the form of Exhibit H attached to this Agreement.

 

2. Representations
and Warranties of the Company. The Company hereby represents and warrants to each Purchaser that, except as set forth on
the Disclosure Schedule attached as Exhibit C to this Agreement, which exceptions shall be deemed to be part of the
representations and warranties made hereunder, the following representations are true and complete as of the date of the
Initial Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding to the
numbered and lettered sections and subsections contained in this Section 2, and the disclosures in any section or subsection
of the Disclosure Schedule shall qualify other sections and subsections in this Section 2 only to the extent it is readily
apparent from a reading of the disclosure that such disclosure is applicable to such other sections and
subsections.

 

For
purposes of these representations and warranties (other than those in Subsections 2.2, 2.3, 2.4, 2.5,
and 2.6), the term the “Company” shall include any subsidiaries of the Company, unless otherwise noted
herein.

 

2.1
Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its
business as now conducted and as presently proposed to be conducted. The Company is duly qualified to transact business and is
in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.

 

2.2
Capitalization. 

 

(a)
The authorized capital of the Company consists, immediately prior to the Initial Closing, of:

 

(i)
3,800,000 shares of common stock, $0.001 par value per share (the “Common Stock”), 2,000,000 shares of which
are issued and outstanding immediately prior to the Initial Closing. All of the outstanding shares of Common Stock have been duly
authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws.
The Company holds no Common Stock in its treasury.

 

    	4

    	 

    

 

(ii)
1,490,651 shares of Preferred Stock, of which all have been designated Series A Preferred Stock, none of which are issued and
outstanding immediately prior to the Initial Closing. The rights, privileges and preferences of the Preferred Stock are as stated
in the Restated Certificate and as provided by the Delaware General Corporation Law. The Company holds no Preferred Stock in its
treasury.

 

(b)
The Company has reserved 275,000 shares of Common Stock for issuance to officers, directors, employees and consultants of the
Company pursuant to its 2020 Stock Incentive Plan duly adopted by the Board of Directors and approved by the Company stockholders
(the “Stock Plan”). Of such reserved shares of Common Stock, no shares have been issued pursuant to restricted
stock purchase agreements, options to purchase no shares have been granted and are currently outstanding, and 275,000 shares of
Common Stock remain available for issuance to officers, directors, employees and consultants pursuant to the Stock Plan. The Company
has furnished to the Purchasers complete and accurate copies of the Stock Plan and forms of agreements used thereunder.

 

(c)
Subsection 2.2(b) of the Disclosure Schedule sets forth the capitalization of the Company immediately following the Initial Closing
including the number of shares of the following: (i) issued and outstanding Common Stock, including, with respect to restricted
Common Stock, vesting schedule and repurchase price; (ii) granted stock options, including vesting schedule and exercise price;
(iii) shares of Common Stock reserved for future award grants under the Stock Plan; (iv) each series of Preferred Stock; and (v)
warrants or stock purchase rights, if any. Except for (A) the conversion privileges of the Shares to be issued under this Agreement,
(B) the rights provided in Section 4 of the Investors’ Rights Agreement, and (C) the securities and rights described in
Subsection 2.2(a)(ii) of this Agreement and Subsection 2.2(b) of the Disclosure Schedule, there are no outstanding options,
warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally
or in writing, to purchase or acquire from the Company any shares of Common Stock or Series A Preferred Stock, or any securities
convertible into or exchangeable for shares of Common Stock or Series A Preferred Stock. All outstanding shares of the Company’s
Common Stock and all shares of the Company’s Common Stock underlying outstanding options are subject to (i) a right of first
refusal in favor of the Company upon any proposed transfer (other than transfers for estate planning purposes); and (ii) a lock-up
or market standoff agreement of not less than one hundred eighty (180) days following the Company’s initial public offering
pursuant to a registration statement filed with the Securities and Exchange Commission under the Securities Act.

 

(d)
None of the Company’s stock purchase agreements or stock option documents contains a provision for acceleration of vesting
(or lapse of a repurchase right) or other changes in the vesting provisions or other terms of such agreement or understanding
upon the occurrence of any event or combination of events, including without limitation in the case where the Company’s
Stock Plan is not assumed in an acquisition. The Company has never adjusted or amended the exercise price of any stock options
previously awarded, whether through amendment, cancellation, replacement grant, repricing, or any other means. Except as set forth
in the Restated Certificate, the Company has no obligation (contingent or otherwise) to purchase or redeem any of its capital
stock.

 

(e)
The Company has obtained valid waivers of any rights by other parties to purchase any of the Shares covered by this Agreement.

 

2.3 Subsidiaries.
The Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership,
trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in
any joint venture, partnership or similar arrangement.

 

    	5

    	 

    

 

2.4 Authorization.
All corporate action required to be taken by the Company’s Board of Directors and stockholders in order to authorize
the Company to enter into the Transaction Agreements, and to issue the Shares at the Closing and the Common Stock issuable
upon conversion of the Shares, has been taken or will be taken prior to the Closing. All action on the part of the officers
of the Company necessary for the execution and delivery of the Transaction Agreements, the performance of all obligations of
the Company under the Transaction Agreements to be performed as of the Closing, and the issuance and delivery of the Shares
has been taken or will be taken prior to the Closing. The Transaction Agreements, when executed and delivered by the Company,
shall constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with
their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other
equitable remedies, or (iii) to the extent the indemnification provisions contained in the Investors’ Rights Agreement
and the Indemnification Agreement may be limited by applicable federal or state securities laws.

 

2.5 Valid
Issuance of Shares. The Shares, when issued, sold and delivered in accordance with the terms and for the consideration
set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other
than restrictions on transfer under the Transaction Agreements, applicable state and federal securities laws and liens or
encumbrances created by or imposed by a Purchaser. Assuming the accuracy of the representations of the Purchasers in Section
3 of this Agreement and subject to the filings described in the Voting Agreement, the Shares will be issued in compliance
with all applicable federal and state securities laws. The Common Stock issuable upon conversion of the Shares has been duly
reserved for issuance, and upon issuance in accordance with the terms of the Restated Certificate, will be validly issued,
fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under the Transaction
Agreements, applicable federal and state securities laws and liens or encumbrances created by or imposed by a Purchaser.
Based in part upon the representations of the Purchasers in Section 3 of this Agreement and in the Voting Agreement, the
Common Stock issuable upon conversion of the Shares will be issued in compliance with all applicable federal and state
securities laws.

 

2.6 Governmental
Consents and Filings. Assuming the accuracy of the representations made by the Purchasers in Section 3 of this Agreement,
no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority is required on the part of the Company in connection with the consummation of
the transactions contemplated by this Agreement, except for (i) the filing of the Restated Certificate, which will have been
filed as of the Initial Closing, and (ii) filings pursuant to Regulation D of the Securities Act, and applicable state
securities laws, which have been made or will be made in a timely manner.

 

2.7 Litigation.
There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or to the
Company’s knowledge, currently threatened in writing (i) against the Company or any officer, director or Key Employee
of the Company arising out of their employment or board relationship with the Company; or (ii) to the Company’s
knowledge, that questions the validity of the Transaction Agreements or the right of the Company to enter into them, or to
consummate the transactions contemplated by the Transaction Agreement; or (iii) to the Company’s knowledge, that would
reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. Neither the Company nor,
to the Company’s knowledge, any of its officers, directors or Key Employees is a party or is named as subject to the
provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the
case of officers, directors or Key Employees, such as would affect the Company). There is no action, suit, proceeding or
investigation by the Company pending or which the Company intends to initiate. The foregoing includes, without limitation,
actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to the Company)
involving the prior employment of any of the Company’s employees, their services provided in connection with the
Company’s business, any information or techniques allegedly proprietary to any of their former employers or their
obligations under any agreements with prior employers.

 

    	6

    	 

    

 

2.8 Intellectual
Property. The Company owns or possesses or believes it can acquire on commercially reasonable terms sufficient legal
rights to all Company Intellectual Property without any known conflict with, or infringement of, the rights of others,
including prior employees or consultants, or academic or medical institutions with which any of them may be affiliated now or
may have been affiliated in the past. To the Company’s knowledge, no product or service marketed or sold (or proposed
to be marketed or sold) by the Company violates or will violate any license or infringes or will infringe any intellectual
property rights of any other party. Other than with respect to commercially available software products under standard
end-user object code license agreements, there are no outstanding options, licenses, agreements, claims, encumbrances or
shared ownership interests of any kind relating to the Company Intellectual Property, nor is the Company bound by or a party
to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information, proprietary rights and processes of any other Person. The Company has not
received any communications alleging that the Company has violated, or by conducting its business, would violate any of the
patents, trademarks, service marks, tradenames, copyrights, trade secrets, mask works or other proprietary rights or
processes of any other Person. The Company has obtained and possesses valid licenses to use all of the software programs
present on the computers and other software-enabled electronic devices that it owns or leases or that it has otherwise
provided to its employees for their use in connection with the Company’s business. To the Company’s knowledge, it
will not be necessary to use any inventions of any of its employees or consultants (or Persons it currently intends to hire)
made prior to their employment by the Company, including prior employees or consultants, or academic or medical institutions
with which any of them may be affiliated now or may have been affiliated in the past. Each employee and consultant has
assigned to the Company all intellectual property rights he or she owns that are related to the Company’s business as
now conducted and as presently proposed to be conducted and all intellectual property rights that he, she or it solely or
jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting
relationship with the Company that (a) relate, at the time of conception, reduction to practice, development, or making of
such intellectual property right, to the Company’s business as then conducted or as then proposed to be conducted, (b)
were developed on any amount of the Company’s time or with the use of any of the Company’s equipment, supplies,
facilities or information or (c) resulted from the performance of services for the Company. Subsection 2.8 of the Disclosure
Schedule lists all patents, patent applications, registered trademarks, trademark applications, service marks, service mark
applications, tradenames, registered copyrights, and licenses to and under any of the foregoing, in each case owned by the
Company. The Company has not embedded any open source, copyleft or community source code in any of its products generally
available or in development, including but not limited to any libraries or code licensed under any General Public License,
Lesser General Public License or similar license arrangement. For purposes of this Subsection 2.8, the Company shall
be deemed to have knowledge of a patent right if the Company has actual knowledge of the patent right or would be found to be
on notice of such patent right as determined by reference to United States patent laws. No government funding, facilities of
a university, college, other educational institution or research center, or funding from third parties was used in the
development of any Company Intellectual Property. No Person who was involved in, or who contributed to, the creation or
development of any Company Intellectual Property, has performed services for the government, university, college, or other
educational institution or research center in a manner that would affect Company’s rights in the Company Intellectual
Property.

 

    	7

    	 

    

 

2.9 Compliance
with Other Instruments. The Company is not in violation or default (i) of any provisions of its Restated Certificate or
Bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under
any lease, agreement, contract or purchase order to which it is a party or by which it is bound that is required to be listed
on the Disclosure Schedule, or (v) to its knowledge, of any provision of federal or state statute, rule or regulation
applicable to the Company, the violation of which would have a Material Adverse Effect. The execution, delivery and
performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements
will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of
notice, either (i) a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement; or
(ii) an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the
suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Company.

 

2.10
Agreements; Actions. 

 

(a)
Except for the Transaction Agreements, there are no agreements, understandings, instruments, contracts or proposed transactions
to which the Company is a party or by which it is bound that involve (i) obligations (contingent or otherwise) of, or payments
to, the Company in excess of $50,000, (ii) the license of any patent, copyright, trademark, trade secret or other proprietary
right to or from the Company, (iii) the grant of rights to manufacture, produce, assemble, license, market, or sell its products
to any other Person that limit the Company’s exclusive right to develop, manufacture, assemble, distribute, market or sell
its products, or (iv) indemnification by the Company with respect to infringements of proprietary rights.

 

(b)
The Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class
or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually
in excess of $50,000 or in excess of $100,000 in the aggregate, (iii) made any loans or advances to any Person, other than ordinary
advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale
of its inventory in the ordinary course of business. For the purposes of (a) and (b) of this Subsection 2.10, all indebtedness,
liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same Person (including
Persons the Company has reason to believe are affiliated with each other) shall be aggregated for the purpose of meeting the individual
minimum dollar amounts of such subsection.

 

(c)
The Company is not a guarantor or indemnitor of any indebtedness of any other Person.

 

2.11
Certain Transactions.

 

(a)
Other than (i) standard employee benefits generally made available to all employees, (ii) standard director and officer indemnification
agreements approved by the Board of Directors, and (iii) the purchase of shares of the Company’s capital stock and the issuance
of options to purchase shares of the Company’s Common Stock, in each instance, approved in the written minutes of the Board
of Directors (previously provided to the Purchasers or their counsel), there are no agreements, understandings or proposed transactions
between the Company and any of its officers, directors, consultants or Key Employees, or any Affiliate thereof.

 

(b)
The Company is not indebted, directly or indirectly, to any of its directors, officers or employees or to their respective spouses
or children or to any Affiliate of any of the foregoing, other than in connection with expenses or advances of expenses incurred
in the ordinary course of business or employee relocation expenses and for other customary employee benefits made generally available
to all employees. None of the Company’s directors, officers or employees, or any members of their immediate families, or
any Affiliate of the foregoing are, directly or indirectly, indebted to the Company or, to the Company’s knowledge, have
any (i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any
of the Company’s customers, suppliers, service providers, joint venture partners, licensees and competitors, (ii) direct
or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a
business relationship, or any firm or corporation which competes with the Company except that directors, officers, employees or
stockholders of the Company may own stock in (but not exceeding two percent (2%) of the outstanding capital stock of) publicly
traded companies that may compete with the Company; or (iii) financial interest in any material contract with the Company.

    	8

    	 

    

 

 

2.12 Rights
of Registration and Voting Rights. Except as provided in the Investors’ Rights Agreement, the Company is not under
any obligation to register under the Securities Act any of its currently outstanding securities or any securities issuable
upon exercise or conversion of its currently outstanding securities. To the Company’s knowledge, except as contemplated
in the Voting Agreement, no stockholder of the Company has entered into any agreements with respect to the voting of capital
shares of the Company. 

 

2.13 Property.
The property and assets that the Company owns are free and clear of all mortgages, deeds of trust, liens, loans and
encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and
liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such
property or assets. With respect to the property and assets it leases, the Company is in compliance with such leases and
holds a valid leasehold interest free of any liens, claims or encumbrances other than those of the lessors of such property
or assets. The Company does not own any real property.

 

2.14 Material
Liabilities. The Company has no liability or obligation, absolute or contingent (individually or in the aggregate),
except (i) obligations and liabilities incurred after the date of incorporation in the ordinary course of business that are
not material, individually or in the aggregate, and (ii) obligations under contracts made in the ordinary course of business
that would not be required to be reflected in financial statements prepared in accordance with GAAP.. 

 

2.15 Changes.
Since the date of incorporation of the Company there has not been: 

 

(a)
any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the Financial
Statements, except changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse Effect;

 

(b)
any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;

 

(c)
any waiver or compromise by the Company of a valuable right or of a material debt owed to it;

 

(d)
any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except in the ordinary
course of business and the satisfaction or discharge of which would not have a Material Adverse Effect;

 

(e)
any material change to a material contract or agreement by which the Company or any of its assets is bound or subject;

 

(f)
any material change in any compensation arrangement or agreement with any employee, officer, director or stockholder;

 

    	9

    	 

    

 

(g)
any resignation or termination of employment of any officer or Key Employee of the Company;

 

(h)
any mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material
properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and
do not materially impair the Company’s ownership or use of such property or assets;

 

(i)
any loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any members of their
immediate families, other than travel advances and other advances made in the ordinary course of its business;

 

(j)
any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock, or any
direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company;

 

(k)
any sale, assignment or transfer of any Company Intellectual Property that could reasonably be expected to result in a Material
Adverse Effect;

 

(l)
receipt of notice that there has been a loss of, or material order cancellation by, any major customer of the Company;

 

(m)
to the Company’s knowledge, any other event or condition of any character, other than events affecting the economy or the
Company’s industry generally, that could reasonably be expected to result in a Material Adverse Effect; or

 

(n)
any arrangement or commitment by the Company to do any of the things described in this Subsection 2.15.

 

2.16
Employee Matters. 

 

(a)
As of the date hereof, the Company employs no full-time employees and no part-time employees and engages no consultants or independent
contractors.

 

(b)
The Company is not delinquent in payments to any of its employees, consultants, or independent contractors for any wages, salaries,
commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to
be reimbursed to such employees, consultants or independent contractors. The Company has complied in all material respects with
all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those
related to wages, hours, worker classification and collective bargaining. The Company has withheld and paid to the appropriate
governmental entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from
employees of the Company and is not liable for any arrears of wages, taxes, penalties or other sums for failure to comply with
any of the foregoing.

 

(c)
The Company has not made any representations regarding equity incentives to any officer, employee, director or consultant that
are inconsistent with the share amounts and terms set forth in the minutes of meetings of the Company’s board of directors.

 

    	10

    	 

    

 

(d)
Subsection 2.16(d) of the Disclosure Schedule sets forth each employee benefit plan maintained, established or sponsored by the
Company, or which the Company participates in or contributes to, which is subject to the Employee Retirement Income Security Act
of 1974, as amended (“ERISA”). The Company has made all required contributions and has no liability to any
such employee benefit plan, other than liability for health plan continuation coverage described in Part 6 of Title I(B) of ERISA,
and has complied in all material respects with all applicable laws for any such employee benefit plan.

 

(e)
To the Company’s knowledge, none of the directors of the Company has been (a) subject to voluntary or involuntary petition
under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar officer
by a court for his or her business or property; (b) convicted in a criminal proceeding or named as a subject of a pending criminal
proceeding (excluding traffic violations and other minor offenses); (c) subject to any order, judgment or decree (not subsequently
reversed, suspended, or vacated) of any court of competent jurisdiction permanently or temporarily enjoining him or her from engaging,
or otherwise imposing limits or conditions on his or her engagement in any securities, investment advisory, banking, insurance,
or other type of business or acting as an officer or director of a public company; or (d) found by a court of competent jurisdiction
in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated any
federal or state securities, commodities, or unfair trade practices law, which such judgment or finding has not been subsequently
reversed, suspended, or vacated.

 

2.17 Tax
Returns and Payments. There are no federal, state, county, local or foreign taxes due and payable by the Company which
have not been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Company
which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports
by any applicable federal, state, local or foreign governmental agency. The Company has duly and timely filed all federal,
state, county, local and foreign tax returns required to have been filed by it and there are in effect no waivers of
applicable statutes of limitations with respect to taxes for any year. 

 

2.18 Insurance.
The Company has in full force and effect insurance policies concerning such casualties as would be reasonable and customary
for companies like the Company. 

 

2.19 Employee
Agreements. Each current and former employee, consultant and officer of the Company has executed an agreement with the
Company regarding confidentiality and proprietary information substantially in the form or forms delivered to the counsel for
the Purchasers (the “Confidential Information Agreements”). No current or former Key Employee has excluded
works or inventions from his or her assignment of inventions pursuant to such Key Employee’s Confidential Information
Agreement. Each current and former Key Employee has executed a non-solicitation agreement substantially in the form or forms
delivered to counsel for the Purchasers. The Company is not aware that any of its Key Employees is in violation of any
agreement covered by this Subsection 2.19. 

 

2.20 Permits.
The Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its business, the
lack of which could reasonably be expected to have a Material Adverse Effect. The Company is not in default in any material
respect under any of such franchises, permits, licenses or other similar authority. 

 

2.21 Corporate
Documents. The Restated Certificate and Bylaws of the Company are in the form provided to the Purchasers. The copy of the
minute books of the Company provided to the Purchasers contains minutes of all meetings of directors and stockholders and all
actions by written consent without a meeting by the directors and stockholders since the date of incorporation and accurately
reflects in all material respects all actions by the directors (and any committee of directors) and stockholders with respect
to all transactions referred to in such minutes. 

 

    	11

    	 

    

 

2.22 Disclosure.
The Company has made available to the Purchasers all the information reasonably available to the Company that the Purchasers
have requested for deciding whether to acquire the Shares, including certain of the Company’s projections describing
its proposed business plan (the “Business Plan”). 

 

3. Representations
and Warranties of the Purchasers. Each Purchaser hereby represents and warrants to the Company, severally and not
jointly, that: 

 

3.1 Authorization.
The Purchaser has full power and authority to enter into the Transaction Agreements. The Transaction Agreements to which the
Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of
the Purchaser, enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of
creditors’ rights generally, and as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies, or (b) to the extent the indemnification provisions contained in the Investors’
Rights Agreement may be limited by applicable federal or state securities laws.

 

3.2 Purchase
Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation
to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Shares to
be acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or
agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention
of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Purchaser
further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any
Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Shares.
The Purchaser has not been formed for the specific purpose of acquiring the Shares. 

 

3.3 Disclosure
of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial
affairs and the terms and conditions of the offering of the Shares with the Company’s management and has had an
opportunity to review the Company’s facilities. The foregoing, however, does not limit or modify the representations
and warranties of the Company in Section 2 of this Agreement or the right of the Purchasers to rely thereon. 

 

3.4 Restricted
Securities. The Purchaser understands that the Shares have not been, and will not be, registered under the Securities
Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other
things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed
herein. The Purchaser understands that the Shares are “restricted securities” under applicable U.S. federal and
state securities laws and that, pursuant to these laws, the Purchaser must hold the Shares indefinitely unless they are
registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such
registration and qualification requirements is available. The Purchaser acknowledges that the Company has no obligation to
register or qualify the Shares, or the Common Stock into which it may be converted, for resale except as set forth in the
Investors’ Rights Agreement. The Purchaser further acknowledges that if an exemption from registration or qualification
is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the
holding period for the Shares, and on requirements relating to the Company which are outside of the Purchaser’s
control, and which the Company is under no obligation and may not be able to satisfy. The Purchaser understands that this
offering is not intended to be part of the public offering, and that the Purchaser will not be able to rely on the protection
of Section 11 of the Securities Act. 

 

    	12

    	 

    

 

3.5 No
Public Market. The Purchaser understands that no public market now exists for the Shares, and that the Company has made
no assurances that a public market will ever exist for the Shares. 

 

3.6 Legends.
The Purchaser understands that the Shares and any securities issued in respect of or exchange for the Shares, may be notated
with one or all of the following legends: 

 

“THE
SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND
NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

 

(a)
Any legend set forth in, or required by, the other Transaction Agreements.

 

(b)
Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the
certificate, instrument, or book entry so legended.

 

3.7 Accredited
Investor. The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the
Securities Act. 

 

3.8 Foreign
Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), the Purchaser
hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with
any invitation to subscribe for the Shares or any use of this Agreement, including (i) the legal requirements within its
jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any
governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that
may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. The Purchaser’s subscription and
payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of the
Purchaser’s jurisdiction. 

 

3.9 No
General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or
partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or
(b) published any advertisement in connection with the offer and sale of the Shares. 

 

3.10
Exculpation Among Purchasers. The Purchaser acknowledges that it is not relying upon any Person, other than the Company
and its officers and directors, in making its investment or decision to invest in the Company. The Purchaser agrees that neither
any Purchaser nor the respective controlling Persons, officers, directors, partners, agents, or employees of any Purchaser shall
be liable to any other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the
purchase of the Shares.

 

3.11 Residence.
If the Purchaser is an individual, then the Purchaser resides in the state or province identified in the address of the
Purchaser set forth on Exhibit A; if the Purchaser is a partnership, corporation, limited liability company or other
entity, then the office or offices of the Purchaser in which its principal place of business is identified in the address or
addresses of the Purchaser set forth on Exhibit A. 

 

    	13

    	 

    

 

4. Conditions
to the Purchasers’ Obligations at Closing. The obligations of each Purchaser to purchase Shares at the Initial
Closing or Milestone Warrants at any subsequent Closing are subject to the fulfillment, on or before such Closing, of each of
the following conditions, unless otherwise waived: 

 

4.1 Representations
and Warranties. The representations and warranties of the Company contained in Section 2 (as modified by the Disclosure
Schedule and any updates thereto made in connection with a Milestone Closing or Subsequent Closing) shall be true and correct
in all respects as of such Closing. 

 

4.2 Performance.
The Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by the Company on or before such Closing. 

 

4.3 Compliance
Certificate. The President of the Company shall deliver to the Purchasers at such Closing a certificate certifying that
the conditions specified in Subsections 4.1 and 4.2 have been fulfilled.

 

4.4 Qualifications.
All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of
any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be
obtained and effective as of such Closing. 

 

4.5 Board
of Directors. As of the Initial Closing, the authorized size of the Board shall be five. 

 

4.6 Indemnification
Agreement. The Company shall have executed and delivered the Indemnification Agreements. 

 

4.7 Investors’
Rights Agreement. The Company and each Purchaser (other than the Purchaser relying upon this condition to excuse such
Purchaser’s performance hereunder) shall have executed and delivered the Investors’ Rights
Agreement. 

 

4.8 Right
of First Refusal and Co-Sale Agreement. The Company, each Purchaser (other than the Purchaser relying upon this condition
to excuse such Purchaser’s performance hereunder), and the other stockholders of the Company named as parties thereto
shall have executed and delivered the Right of First Refusal and Co-Sale Agreement. 

 

4.9 Voting
Agreement. The Company, each Purchaser (other than the Purchaser relying upon this condition to excuse such
Purchaser’s performance hereunder), and the other stockholders of the Company named as parties thereto shall have
executed and delivered the Voting Agreement. 

 

4.10
Warrant Purchase Agreement. In respect of a Milestone Closing only, the Company shall have executed and delivered the Warrant
Purchase Agreement.

 

4.11 Restated
Certificate. The Company shall have filed the Restated Certificate with the Secretary of State of Delaware on or prior to
the Closing, which shall continue to be in full force and effect as of the Closing. 

 

4.12 Secretary’s
Certificate. The Secretary of the Company shall have delivered to the Purchasers at the Closing a certificate certifying
(i) the Bylaws of the Company, (ii) resolutions of the Board of Directors of the Company approving the Transaction Agreements
and the transactions contemplated under the Transaction Agreements, and (iii) resolutions of the stockholders of the Company
approving the Restated Certificate. 

 

    	14

    	 

    

 

4.13 Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and
all documents incident thereto shall be reasonably satisfactory in form and substance to each Purchaser, and each Purchaser
(or its counsel) shall have received all such counterpart original and certified or other copies of such documents as
reasonably requested. Such documents may include good standing certificates. 

 

5. Conditions
of the Company’s Obligations at Closing. The obligations of the Company to sell Shares to the Purchasers at the
Initial Closing or Milestone Warrants at any subsequent Closing are subject to the fulfillment, on or before the Closing, of
each of the following conditions, unless otherwise waived: 

 

5.1 Representations
and Warranties. The representations and warranties of each Purchaser contained in Section 3 shall be true and correct in
all respects as of such Closing. 

 

5.2 Performance.
The Purchasers shall have performed and complied with all covenants, agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by them on or before such Closing. 

 

5.3 Qualifications.
All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of
any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be
obtained and effective as of the Closing. 

 

5.4 Investors’
Rights Agreement. Each Purchaser shall have executed and delivered the Investors’ Rights
Agreement. 

 

5.5 Right
of First Refusal and Co-Sale Agreement. Each Purchaser and the other stockholders of the Company named as parties thereto
shall have executed and delivered the Right of First Refusal and Co-Sale Agreement. 

 

5.6 Voting
Agreement. Each Purchaser and the other stockholders of the Company named as parties thereto shall have executed and
delivered the Voting Agreement. 

 

5.7
Warrant Purchase Agreement. In respect of a Milestone Closing only, each Purchaser shall have executed and delivered the
Warrant Purchase Agreement.

 

6.
Miscellaneous. 

 

6.1 Survival
of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the
Purchasers contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the
Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf
of the Purchasers or the Company. 

 

6.2 Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement. 

 

    	15

    	 

    

 

6.3 Governing
Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law
principles that would result in the application of any law other than the law of the State of Delaware. 

 

6.4 Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes. 

 

6.5 Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. 

 

6.6 Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed
effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if
sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business
hours, then on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized
overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their address as set forth on the signature page or Exhibit
A, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance
with this Subsection 6.6. If notice is given to the Company, a copy shall also be sent to Faber Daeufer & Itrato
PC, 890 Winter Street, Suite 315, Waltham, MA 02451. 

 

6.7 No
Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or
commission in connection with this transaction. Each Purchaser agrees to indemnify and to hold harmless the Company from any
liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this
transaction (and the costs and expenses of defending against such liability or asserted liability) for which each Purchaser
or any of its officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless each
Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee
arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for
which the Company or any of its officers, employees or representatives is responsible. 

 

6.8 
Fees and Expenses. At the Closing, the Company shall pay the reasonable fees and expenses of counsel to 22NW, LP, in an
amount not to exceed, in the aggregate, $20,000. 

 

6.9 Attorneys’
Fees. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret the terms of any of
the Transaction Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary
disbursements in addition to any other relief to which such party may be entitled. 

 

6.10 Amendments
and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Company
and the holders of at least a majority of the then-outstanding Shares. Any amendment or waiver effected in accordance with
this Subsection 6.10 shall be binding upon the Purchasers and each transferee of the Shares (or the Common Stock
issuable upon conversion thereof), each future holder of all such securities, and the Company. 

 

    	16

    	 

    

 

6.11 Severability.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other
provision. 

 

6.12 Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such
non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single
breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any
waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective
only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise
afforded to any party, shall be cumulative and not alternative. 

 

6.13 Entire
Agreement. This Agreement (including the Exhibits hereto), the Restated Certificate and the other Transaction Agreements
constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and
any other written or oral agreement relating to the subject matter hereof existing between the parties are expressly
canceled. 

 

6.14 Corporate
Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR THE PAYMENT OR RECEIPT OF ANY
PART OF THE CONSIDERATION THEREFOR PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM THE
QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS
AGREEMENT ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING OBTAINED UNLESS THE SALE IS SO EXEMPT. 

 

6.15
Termination of Closing Obligations. Each Purchaser shall have the right to terminate its obligations to complete a Closing,
if prior to the occurrence thereof, any of the following occurs: 

 

(a)
the Company consummates a Deemed Liquidation Event (as defined in the Restated Certificate);

 

(b)
the closing of an initial public offering of the Company, in which case the Purchasers may terminate their obligations hereunder
immediately prior to, or contingent upon, such closing; or

 

(c)
the Company (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (iii) makes an assignment for the benefit of creditors, (iv) institutes any proceedings under the United
States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law
affecting the rights of creditors generally, or files a petition or answer seeking reorganization or an arrangement with creditors
to take advantage of any insolvency law, or files an answer admitting the material allegations of a bankruptcy, reorganization
or insolvency petition filed against it, or (v) becomes subject to any involuntary proceedings under the United States Bankruptcy
Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights
of creditors generally, when proceeding is not dismissed within thirty (30) days of filing, or have an order for relief entered
against it in any proceedings under the United States Bankruptcy Code.

 

    	17

    	 

    

 

6.16 Dispute
Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any
suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or
other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States
District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense,
or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the
above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding
is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or
the subject matter hereof may not be enforced in or by such court. 

 

Waiver
of Jury Trial: EACH PARTY HEREBY WAIVES ITS RIGHTS
TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS,
THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND
ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION,
CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS
SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH
PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT
SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL

 

6.17 No
Commitment for Additional Financing. The Company acknowledges and agrees that no Purchaser has made any representation,
undertaking, commitment or agreement to provide or assist the Company in obtaining any financing, investment or other
assistance, other than the purchase of the Shares as set forth herein and subject to the conditions set forth herein. In
addition, the Company acknowledges and agrees that (i) no statements, whether written or oral, made by any Purchaser or its
representatives on or after the date of this Agreement shall create an obligation, commitment or agreement to provide or
assist the Company in obtaining any financing or investment, (ii) the Company shall not rely on any such statement by any
Purchaser or its representatives, and (iii) an obligation, commitment or agreement to provide or assist the Company in
obtaining any financing or investment may only be created by a written agreement, signed by such Purchaser and the Company,
setting forth the terms and conditions of such financing or investment and stating that the parties intend for such writing
to be a binding obligation or agreement. Each Purchaser shall have the right, in its sole and absolute discretion, to refuse
or decline to participate in any other financing of or investment in the Company, and shall have no obligation to assist or
cooperate with the Company in obtaining any financing, investment or other assistance. 

 

    	18

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	ANEBULO
    PHARMACEUTICALS, INC.
	 	 
	 	By:
    	                                                                         
	 	 	 
	 	Name:
    	Joseph
    F. Lawler
	 	 	(print)
	 	 	 
	 	Title:	President
	 	 	 
	 	Address:	 
	 	 	 
	 	c/o
    JFL Capital Management
	 	1415
    Ranch Road 620 South, Suite 201
	 	Lakeway,
    Texas 78734
	 	 	 
	 	22NW,
    LP
	 	 
	 	
	 	(Print
    Name of Purchaser)
	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	(print)
	 	 	 
	 	Title:	 
	 	 	 
	 	Address:	 
	 	 	 
	 	 	 

 

Signature
Page To Stock Purchase Agreement 

 

    	 

    	 

    

 

EXHIBITS

 

	 	Exhibit
    A -	SCHEDULE
    OF PURCHASERS
	 	 	 
	 	Exhibit
    B -	FORM
    OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
	 	 	 
	 	Exhibit
    C -	DISCLOSURE
    SCHEDULE
	 	 	 
	 	Exhibit
    D -	FORM
    OF INDEMNIFICATION AGREEMENT
	 	 	 
	 	Exhibit
    E -	FORM
    OF INVESTORS’ RIGHTS AGREEMENT
	 	 	 
	 	Exhibit
    F -	FORM
    OF MANAGEMENT RIGHTS LETTER
	 	 	 
	 	Exhibit
    G -	Form
    of Right of First Refusal and Co-Sale Agreement
	 	 	 
	 	Exhibit
    H -	FORM
    OF VOTING AGREEMENT
	 	 	 
	 	Exhibit
    I -	MILESTONE
    EVENTS
	 	 	 
	 	Exhibit
    J -	WARRANT
    PURCHASE AGREEMENT

 

    	 

    	 

    

 

EXHIBIT
A

 

SCHEDULE
OF PURCHASERS

 

	Purchaser	 	Address	 	First Tranche Shares	 	 	Warrant Shares	 
	22NW, L.P.	 	1455 NW Leary Way Ste 400, Seattle,

                                                                  WA 98107
	 	 	341,250	 	 	 	638,556	 
	Aron English	 	2428 NW Market St. #760, Seattle, WA 98107	 	 	-	 	 	 	510,845	 

 

    	 

    	 

    

 

EXHIBIT
B

 

FORM
OF AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

 

    	 

    	 

    

  

EXHIBIT
C

 

DISCLOSURE
SCHEDULE

 

    	 

    	 

    

  

EXHIBIT
D

 

FORM
OF INDEMNIFICATION AGREEMENT

 

    	 

    	 

    

 

EXHIBIT
E

 

FORM
OF INVESTORS’ RIGHTS AGREEMENT

 

    	 

    	 

    

 

EXHIBIT
F

 

FORM
OF MANAGEMENT RIGHTS LETTER

 

    	 

    	 

    

 

Exhibit
G

 

Form
of Right of First Refusal and Co-Sale Agreement

 

    	 

    	 

    

 

EXHIBIT
H

 

FORM
OF VOTING AGREEMENT

 

    	 

    	 

    

 

EXHIBIT
I

 

MILESTONE
EVENT

 

(i)
The earlier of (x) filing by the Company with the Food and Drug Administration of an IND, or (y) the making of an analogous regulatory
filing in any foreign jurisdiction; and

 

(ii)
Arrangement by the Company of active pharmaceutical ingredient in amounts sufficient to facilitate the consummation of any trial
to be effected pursuant to a filing described in subpart (i) above;

 

    	 

    	 

    

 

EXHIBIT
J

 

WARRANT
PURCHASE AGREEMENTExhibit
10.2

 

RIGHT
OF FIRST REFUSAL

AND CO-SALE AGREEMENT

 

THIS
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Agreement”), is made as of the 18th day of June,
2020 by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Investors (as
defined below) listed on Schedule A and the Key Holders (as defined below) listed on Schedule B.

 

WHEREAS,
each Key Holder is the beneficial owner of the number of shares of Capital Stock, or of options to purchase Common Stock,
set forth opposite the name of such Key Holder on Schedule B;

 

WHEREAS,
the Company and the Investors are parties to that certain Series A Preferred Stock Purchase Agreement, of even date herewith
(the “Purchase Agreement”), pursuant to which the Investors have agreed to purchase shares of the Series A
Preferred Stock of the Company, par value $0.001 per share (“Series A Preferred Stock”); and

 

WHEREAS,
the Key Holders and the Company desire to further induce the Investors to purchase the Series A Preferred Stock;

 

NOW,
THEREFORE, the Company, the Key Holders and, the Investors agree as follows:

 

1.
Definitions. 

 

1.1
“Affiliate” means, with respect to any specified Investor, any other Investor who directly or indirectly, controls,
is controlled by or is under common control with such Investor, including, without limitation, any general partner, managing member,
officer, director or trustee of such Investor, or any venture capital fund or registered investment company now or hereafter existing
which is controlled by one or more general partners, managing members or investment advisers of, or shares the same management
company or investment adviser with, such Investor.

 

1.2
“Board of Directors” means the board of directors of the Company.

 

1.3
“Capital Stock” means (a) shares of Common Stock and Preferred Stock (whether now outstanding or hereafter
issued in any context), (b) shares of Common Stock issued or issuable upon conversion of Preferred Stock, and (c) shares of Common
Stock issued or issuable upon exercise or conversion, as applicable, of stock options, warrants or other convertible securities
of the Company, in each case now owned or subsequently acquired by any Key Holder, any Investor, or their respective successors
or permitted transferees or assigns. For purposes of the number of shares of Capital Stock held by an Investor or Key Holder (or
any other calculation based thereon), all shares of Preferred Stock shall be deemed to have been converted into Common Stock at
the then-applicable conversion ratio.

 

1.4
“Change of Control” means a transaction or series of related transactions in which a person, or a group of
related persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding
voting power of the Company.

 

1.5
“Common Stock” means shares of Common Stock of the Company, $0.001 par value per share.

 

1.6
“Company Notice” means written notice from the Company notifying the selling Key Holders and each Investor
that the Company intends to exercise its Right of First Refusal as to some or all of the Transfer Stock with respect to any Proposed
Key Holder Transfer.

 

    	 

    	 

    

 

1.7
“Investor Notice” means written notice from any Investor notifying the Company and the selling Key Holder(s)
that such Investor intends to exercise its Secondary Refusal Right as to a portion of the Transfer Stock with respect to any Proposed
Key Holder Transfer.

 

1.8
“Investors” means the persons named on Schedule A hereto, each person to whom the rights of an Investor
are assigned pursuant to Subsection 6.9, each person who hereafter becomes a signatory to this Agreement pursuant to Subsection
6.11 and any one of them, as the context may require; provided, however, that any such person shall cease to
be considered an Investor for purposes of this Agreement at any time such person and his, her or its Affiliates collectively hold
fewer than 125,000 shares of Capital Stock (as adjusted for any stock combination, stock split, stock dividend, recapitalization
or other similar transaction and excluding any shares of Common Stock issued to any person pursuant to a Special Mandatory Conversion
(as defined in the Restated Certificate of Incorporation of the Company).

 

1.9
“Key Holders” means the persons named on Schedule B hereto, each person to whom the rights of a Key
Holder are assigned pursuant to Subsection 3.1, each person who hereafter becomes a signatory to this Agreement pursuant
to Subsection 6.9 or 6.17 and any one of them, as the context may require.

 

1.10
“Preferred Stock” means collectively, all shares of Series A Preferred Stock.

 

1.11
“Proposed Key Holder Transfer” means any assignment, sale, offer to sell, pledge, mortgage, hypothecation,
encumbrance, disposition of or any other like transfer or encumbering of any Transfer Stock (or any interest therein) proposed
by any of the Key Holders.

 

1.12
“Proposed Transfer Notice” means written notice from a Key Holder setting forth the terms and conditions of
a Proposed Key Holder Transfer.

 

1.13
“Prospective Transferee” means any person to whom a Key Holder proposes to make a Proposed Key Holder Transfer.

 

1.14
“Restated Certificate” means the Company’s Amended and Restated Certificate of Incorporation, as amended
and/or restated from time to time.

 

1.15
“Right of Co-Sale” means the right, but not an obligation, of an Investor to participate in a Proposed Key
Holder Transfer on the terms and conditions specified in the Proposed Transfer Notice.

 

1.16
“Right of First Refusal” means the right, but not an obligation, of the Company, or its permitted transferees
or assigns, to purchase some or all of the Transfer Stock with respect to a Proposed Key Holder Transfer, on the terms and conditions
specified in the Proposed Transfer Notice.

 

1.17
“Secondary Notice” means written notice from the Company notifying the Investors and the selling Key Holder
that the Company does not intend to exercise its Right of First Refusal as to all shares of any Transfer Stock with respect to
a Proposed Key Holder Transfer, on the terms and conditions specified in the Proposed Transfer Notice.

 

1.18
“Secondary Refusal Right” means the right, but not an obligation, of each Investor to purchase up to its pro
rata portion (based upon the total number of shares of Capital Stock then held by all Investors) of any Transfer Stock not purchased
pursuant to the Right of First Refusal, on the terms and conditions specified in the Proposed Transfer Notice.

 

    	 

    	 

    

 

1.19
“Transfer Stock” means shares of Capital Stock owned by a Key Holder, or issued to a Key Holder after the date
hereof (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or
the like), but does not include any shares of Preferred Stock or of Common Stock that are issued or issuable upon conversion of
Preferred Stock.

 

1.20
“Undersubscription Notice” means written notice from an Investor notifying the Company and the selling Key
Holder that such Investor intends to exercise its option to purchase all or any portion of the Transfer Stock not purchased pursuant
to the Right of First Refusal or the Secondary Refusal Right.

 

2. Agreement
Among the Company, the Investors and the Key Holders. 

 

2.1
Right of First Refusal. 

 

(a)
Grant. Subject to the terms of Section 3 below, each Key Holder hereby unconditionally and irrevocably grants to
the Company a Right of First Refusal to purchase all or any portion of Transfer Stock that such Key Holder may propose to transfer
in a Proposed Key Holder Transfer, at the same price and on the same terms and conditions as those offered to the Prospective
Transferee.

 

(b)
Notice. Each Key Holder proposing to make a Proposed Key Holder Transfer must deliver a Proposed Transfer Notice to the
Company and each Investor not later than forty-five (45) days prior to the consummation of such Proposed Key
Holder Transfer. Such Proposed Transfer Notice shall contain the material terms and conditions (including price and form of consideration)
of the Proposed Key Holder Transfer, the identity of the Prospective Transferee and the intended date of the Proposed Key Holder
Transfer. To exercise its Right of First Refusal under this Section 2, the Company must deliver a Company Notice to the
selling Key Holder and the Investors within fifteen (15) days after delivery of the Proposed Transfer Notice specifying the number
of shares of Transfer Stock to be purchased by the Company. In the event of a conflict between this Agreement and any other agreement
that may have been entered into by a Key Holder with the Company that contains a preexisting right of first refusal, the Company
and the Key Holder acknowledge and agree that the terms of this Agreement shall control and the preexisting right of first refusal
shall be deemed satisfied by compliance with Subsection 2.1(a) and this Subsection 2.1(b).

 

(c)
Grant of Secondary Refusal Right to the Investors. Subject to the terms of Section 3 below, each Key Holder hereby
unconditionally and irrevocably grants to the Investors a Secondary Refusal Right to purchase all or any portion of the Transfer
Stock not purchased by the Company pursuant to the Right of First Refusal, as provided in this Subsection 2.1(c). If the
Company does not provide the Company Notice exercising its Right of First Refusal with respect to all Transfer Stock subject to
a Proposed Key Holder Transfer, the Company must deliver a Secondary Notice to the selling Key Holder and to each Investor to
that effect no later than fifteen (15) days after the selling Key Holder delivers the Proposed Transfer Notice to the Company.
To exercise its Secondary Refusal Right, an Investor must deliver an Investor Notice to the selling Key Holder and the Company
within ten (10) days after the Company’s deadline for its delivery of the Secondary Notice as provided in the preceding
sentence.

 

    	 

    	 

    

 

(d)
Undersubscription of Transfer Stock. If options to purchase have been exercised by the Company and the Investors pursuant
to Subsections 2.1(b) and (c) with respect to some but not all of the Transfer Stock by the end of the ten (10) day period specified
in the last sentence of Subsection 2.1(c) (the “Investor Notice Period”), then the Company shall, within
five (5) days after the expiration of the Investor Notice Period, send written notice (the “Company Undersubscription
Notice”) to those Investors who fully exercised their Secondary Refusal Right within the Investor Notice Period (the
“Exercising Investors”). Each Exercising Investor shall, subject to the provisions of this Subsection 2.1(d),
have an additional option to purchase all or any part of the balance of any such remaining unsubscribed shares of Transfer Stock
on the terms and conditions set forth in the Proposed Transfer Notice. To exercise such option, an Exercising Investor must deliver
an Undersubscription Notice to the selling Key Holder and the Company within ten (10) days after the expiration of the Investor
Notice Period. In the event there are two (2) or more such Exercising Investors that choose to exercise the last-mentioned option
for a total number of remaining shares in excess of the number available, the remaining shares available for purchase under this
Subsection 2.1(d) shall be allocated to such Exercising Investors pro rata based on the number of shares of Transfer Stock
such Exercising Investors have elected to purchase pursuant to the Secondary Refusal Right (without giving effect to any shares
of Transfer Stock that any such Exercising Investor has elected to purchase pursuant to the Company Undersubscription Notice).
If the options to purchase the remaining shares are exercised in full by the Exercising Investors, the Company shall immediately
notify all of the Exercising Investors and the selling Key Holder of that fact.

 

(e)
Consideration; Closing. If the consideration proposed to be paid for the Transfer Stock is in property, services or other
non-cash consideration, the fair market value of the consideration shall be as determined in good faith by the Board of Directors
and as set forth in the Company Notice. If the Company or any Investor cannot for any reason pay for the Transfer Stock in the
same form of non-cash consideration, the Company or such Investor may pay the cash value equivalent thereof, as determined in
good faith by the Board of Directors and as set forth in the Company Notice. The closing of the purchase of Transfer Stock by
the Company and the Investors shall take place, and all payments from the Company and the Investors shall have been delivered
to the selling Key Holder, by the later of (i) the date specified in the Proposed Transfer Notice as the intended date of the
Proposed Key Holder Transfer; and (ii) forty-five (45) days after delivery of the Proposed Transfer Notice.

 

2.2
Right of Co-Sale. 

 

(a)
Exercise of Right. If any Transfer Stock subject to a Proposed Key Holder Transfer is not purchased pursuant to Subsection
2.1 above and thereafter is to be sold to a Prospective Transferee, each respective Investor may elect to exercise its Right
of Co-Sale and participate on a pro rata basis in the Proposed Key Holder Transfer as set forth in Subsection 2.2(b) below
and, subject to Subsection 2.2(d), otherwise on the same terms and conditions specified in the Proposed Transfer Notice.
Each Investor who desires to exercise its Right of Co-Sale (each, a “Participating Investor”) must give the
selling Key Holder written notice to that effect within fifteen (15) days after the deadline for delivery of the Secondary Notice
described above, and upon giving such notice such Participating Investor shall be deemed to have effectively exercised the Right
of Co-Sale.

 

(b)
Shares Includable. Each Participating Investor may include in the Proposed Key Holder Transfer all or any part of such
Participating Investor’s Capital Stock equal to the product obtained by multiplying (i) the aggregate number of shares of
Transfer Stock subject to the Proposed Key Holder Transfer (excluding shares purchased by the Company or the Participating Investors
pursuant to the Right of First Refusal or the Secondary Refusal Right) by (ii) a fraction, the numerator of which is the number
of shares of Capital Stock owned by such Participating Investor immediately before consummation of the Proposed Key Holder Transfer
(including any shares that such Participating Investor has agreed to purchase pursuant to the Secondary Refusal Right but excluding
any shares that such Participating Investor holds pursuant to a Special Mandatory Conversion) and the denominator of which is
the total number of shares of Capital Stock owned, in the aggregate, by all Participating Investors immediately prior to the consummation
of the Proposed Key Holder Transfer (including any shares that all Participating Investors have collectively agreed to purchase
pursuant to the Secondary Refusal Right but excluding any shares that Participating Investors hold pursuant to a Special Mandatory
Conversion), plus the number of shares of Transfer Stock held by the selling Key Holder. To the extent one (1) or more of the
Participating Investors exercise such right of participation in accordance with the terms and conditions set forth herein, the
number of shares of Transfer Stock that the selling Key Holder may sell in the Proposed Key Holder Transfer shall be correspondingly
reduced.

 

    	 

    	 

    

 

(c)
Purchase and Sale Agreement. The Participating Investors and the selling Key Holder agree that the terms and conditions
of any Proposed Key Holder Transfer in accordance with this Subsection 2.2 will be memorialized in, and governed by, a
written purchase and sale agreement with the Prospective Transferee (the “Purchase and Sale Agreement”) with
customary terms and provisions for such a transaction, and the Participating Investors and the selling Key Holder further covenant
and agree to enter into such Purchase and Sale Agreement as a condition precedent to any sale or other transfer in accordance
with this Subsection 2.2.

 

(d)
Allocation of Consideration.

 

(i)
Subject to Subsection 2.2(d)(ii), the aggregate consideration payable to the Participating Investors and the selling Key
Holder shall be allocated based on the number of shares of Capital Stock sold to the Prospective Transferee by each Participating
Investor and the selling Key Holder as provided in Subsection 2.2(b), provided that if a Participating Investor
wishes to sell Preferred Stock, the price set forth in the Proposed Transfer Notice shall be appropriately adjusted based on the
conversion ratio of the Preferred Stock into Common Stock.

 

(ii)
In the event that the Proposed Key Holder Transfer constitutes a Change of Control, the terms of the Purchase and Sale Agreement
shall provide that the aggregate consideration from such transfer shall be allocated to the Participating Investors and the selling
Key Holder in accordance with Sections 2.1 and 2.2 of Article IV(B) of the Restated Certificate and, if applicable, the next sentence,
as if (A) such transfer were a Deemed Liquidation Event (as defined in the Restated Certificate), and (B) the Capital Stock sold
in accordance with the Purchase and Sale Agreement were the only Capital Stock outstanding. In the event that a portion of the
aggregate consideration payable to the Participating Investor(s) and selling Key Holder is placed into escrow and/or is payable
only upon satisfaction of contingencies, the Purchase and Sale Agreement shall provide that (x) the portion of such consideration
that is not placed in escrow and is not subject to contingencies (the “Initial Consideration”) shall be allocated
in accordance with Sections 2.1 and 2.2 of Article IV(B) of the Restated Certificate as if the Initial Consideration were the
only consideration payable in connection with such transfer, and (y) any additional consideration which becomes payable to the
Participating Investor(s) and selling Key Holder upon release from escrow or satisfaction of such contingencies shall be allocated
in accordance with Sections 2.1 and 2.2 of Article IV(B) of the Restated Certificate after taking into account the previous payment
of the Initial Consideration as part of the same transfer.

 

(e)
Purchase by Selling Key Holder; Deliveries. Notwithstanding Subsection 2.2(c) above, if any Prospective Transferee
or Transferees refuse(s) to purchase securities subject to the Right of Co-Sale from any Participating Investor or Investors or
upon the failure to negotiate in good faith a Purchase and Sale Agreement reasonably satisfactory to the Participating Investors,
no Key Holder may sell any Transfer Stock to such Prospective Transferee or Transferees unless and until, simultaneously with
such sale, such Key Holder purchases all securities subject to the Right of Co-Sale from such Participating Investor or Investors
on the same terms and conditions (including the proposed purchase price) as set forth in the Proposed Transfer Notice and as provided
in Subsection 2.2(d)(i); provided, however, if such sale constitutes a Change of Control, the portion
of the aggregate consideration paid by the selling Key Holder to such Participating Investor or Investors shall be made in accordance
with the first sentence of Subsection 2.2(d)(ii). In connection with such purchase by the selling Key Holder, such Participating
Investor or Investors shall deliver to the selling Key Holder any stock certificate or certificates, properly endorsed for transfer,
representing the Capital Stock being purchased by the selling Key Holder (or request that the Company effect such transfer in
the name of the selling Key Holder). Any such shares transferred to the selling Key Holder will be transferred to the Prospective
Transferee against payment therefor in consummation of the sale of the Transfer Stock pursuant to the terms and conditions specified
in the Proposed Transfer Notice, and the selling Key Holder shall concurrently therewith remit or direct payment to each such
Participating Investor the portion of the aggregate consideration to which each such Participating Investor is entitled by reason
of its participation in such sale as provided in this Subsection 2.2(e).

 

    	 

    	 

    

 

(f)
Additional Compliance. If any Proposed Key Holder Transfer is not consummated within forty-five (45) days after receipt
of the Proposed Transfer Notice by the Company, the Key Holders proposing the Proposed Key Holder Transfer may not sell any Transfer
Stock unless they first comply in full with each provision of this Section 2. The exercise or election not to exercise
any right by any Investor hereunder shall not adversely affect its right to participate in any other sales of Transfer Stock subject
to this Subsection 2.2.

 

2.3
Effect of Failure to Comply. 

 

(a)
Transfer Void; Equitable Relief. Any Proposed Key Holder Transfer not made in compliance with the requirements of this
Agreement shall be null and void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall
not be recognized by the Company. Each party hereto acknowledges and agrees that any breach of this Agreement would result in
substantial harm to the other parties hereto for which monetary damages alone could not adequately compensate. Therefore, the
parties hereto unconditionally and irrevocably agree that any non-breaching party hereto shall be entitled to seek protective
orders, injunctive relief and other remedies available at law or in equity (including, without limitation, seeking specific performance
or the rescission of purchases, sales and other transfers of Transfer Stock not made in strict compliance with this Agreement).

 

(b)
Violation of First Refusal Right. If any Key Holder becomes obligated to sell any Transfer Stock to the Company or any
Investor under this Agreement and fails to deliver such Transfer Stock in accordance with the terms of this Agreement, the Company
and/or such Investor may, at its option, in addition to all other remedies it may have, send to such Key Holder the purchase price
for such Transfer Stock as is herein specified and transfer to the name of the Company or such Investor (or request that the Company
effect such transfer in the name of an Investor) on the Company’s books any certificates, instruments, or book entry representing
the Transfer Stock to be sold.

 

(c)
Violation of Co-Sale Right. If any Key Holder purports to sell any Transfer Stock in contravention of the Right of Co-Sale
(a “Prohibited Transfer”), each Participating Investor who 2 to exercise its Right of Co-Sale under Subsection
2.2 may, in addition to such remedies as may be available by law, in equity or hereunder, require such Key Holder to purchase
from such Participating Investor the type and number of shares of Capital Stock that such Participating Investor would have been
entitled to sell to the Prospective Transferee had the Prohibited Transfer been effected in compliance with the terms of Subsection
2.2. The sale will be made on the same terms, including, without limitation, as provided in Subsection 2.2(d)(i) and
the first sentence of Subsection 2.2(d)(ii), as applicable, and subject to the same conditions as would have applied had
the Key Holder not made the Prohibited Transfer, except that the sale (including, without limitation, the delivery of the purchase
price) must be made within ninety (90) days after the Participating Investor learns of the Prohibited Transfer, as opposed to
the timeframe proscribed in Subsection 2.2. Such Key Holder shall also reimburse each Participating Investor for any and
all reasonable and documented out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant
to the exercise or the attempted exercise of the Participating Investor’s rights under Subsection 2.2.

 

    	 

    	 

    

 

3.
Exempt Transfers. 

 

3.1
Exempted Transfers. Notwithstanding the foregoing or anything to the contrary herein, the provisions of Subsections 2.1
and 2.2 shall not apply (a) in the case of a Key Holder that is an entity, upon a transfer by such Key Holder to its
stockholders, members, partners or other equity holders, (b) to a repurchase of Transfer Stock from a Key Holder by the Company
at a price no greater than that originally paid by such Key Holder for such Transfer Stock and pursuant to an agreement containing
vesting and/or repurchase provisions approved by a majority of the Board of Directors, (c) to a pledge of Transfer Stock that
creates a mere security interest in the pledged Transfer Stock, provided that the pledgee thereof agrees in writing in
advance to be bound by and comply with all applicable provisions of this Agreement to the same extent as if it were the Key Holder
making such pledge, or (d) in the case of a Key Holder that is a natural person, upon a transfer of Transfer Stock by such Key
Holder made for bona fide estate planning purposes, either during his or her lifetime or on death by will or intestacy to his
or her spouse, child (natural or adopted), or any other direct lineal descendant of such Key Holder (or his or her spouse) (all
of the foregoing collectively referred to as “family members”), or any other relative/person approved by unanimous
consent of the Board of Directors, or any custodian or trustee of any trust, partnership or limited liability company for the
benefit of, or the ownership interests of which are owned wholly by such Key Holder or any such family members; provided
that in the case of clause(s) (a), (c), (d) or (e), the Key Holder shall deliver prior written notice to the Investors of such
pledge, gift or transfer and such shares of Transfer Stock shall at all times remain subject to the terms and restrictions set
forth in this Agreement and such transferee shall, as a condition to such issuance, deliver a counterpart signature page to this
Agreement as confirmation that such transferee shall be bound by all the terms and conditions of this Agreement as a Key Holder
(but only with respect to the securities so transferred to the transferee), including the obligations of a Key Holder with respect
to Proposed Key Holder Transfers of such Transfer Stock pursuant to Section 2; and provided further in the
case of any transfer pursuant to clause (a) or (d) above, that such transfer is made pursuant to a transaction in which there
is no consideration actually paid for such transfer.

 

3.2
Exempted Offerings. Notwithstanding the foregoing or anything to the contrary herein, the provisions of Section 2
shall not apply to the sale of any Transfer Stock (a) to the public in an offering pursuant to an effective registration statement
under the Securities Act of 1933, as amended (a “Public Offering”); or (b) pursuant to a Deemed Liquidation
Event (as defined in the Restated Certificate). 

 

3.3
Prohibited Transferees. Notwithstanding the foregoing, no Key Holder shall transfer any Transfer Stock to (a) any entity
which, in the determination of the Board of Directors, directly or indirectly competes with the Company; or (b) any customer,
distributor or supplier of the Company, if the Board of Directors should determine that such transfer would result in such customer,
distributor or supplier receiving information that would place the Company at a competitive disadvantage with respect to such
customer, distributor or supplier. 

 

4. Legend.
Each certificate, instrument, or book entry representing shares of Transfer Stock held by the Key Holders or issued to any
permitted transferee in connection with a transfer permitted by Subsection 3.1 hereof shall be notated with the
following legend: 

 

THE
SALE, PLEDGE, HYPOTHECATION, OR TRANSFER OF THE SECURITIES REPRESENTED HEREBY IS SUBJECT TO, AND IN CERTAIN CASES PROHIBITED BY,
THE TERMS AND CONDITIONS OF A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND AMONG THE STOCKHOLDER, THE CORPORATION
AND CERTAIN OTHER HOLDERS OF STOCK OF THE CORPORATION. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY
OF THE CORPORATION.

 

    	 

    	 

    

 

Each
Key Holder agrees that the Company may instruct its transfer agent to impose transfer restrictions on the shares notated with
the legend referred to in this Section 4 above to enforce the provisions of this Agreement, and the Company agrees to promptly
do so. The legend shall be removed upon termination of this Agreement at the request of the holder.

 

5.
Lock-Up. 

 

5.1
Agreement to Lock-Up. Each Key Holder hereby agrees that it will not, without the prior written consent of the managing
underwriter, during the period commencing on the date of the final prospectus relating to the Company’s initial public offering
(the “IPO”) and ending on the date specified by the Company and the managing underwriter (such period not to
exceed one hundred eighty (l80) days, or such other period as may be requested by the Company or an underwriter to accommodate
regulatory restrictions on (1) the publication or other distribution of research reports; and (2) analyst recommendations and
opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor
provisions or amendments thereto), (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly
or indirectly, any shares of Capital Stock held immediately prior to the effectiveness of the registration statement for the IPO;
or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of the Capital Stock, whether any such transaction described in clause (a) or (b) above is to be settled by delivery
of Capital Stock or other securities, in cash or otherwise. The foregoing provisions of this Section 5 shall not apply
to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Key Holders
if all officers, directors and holders of more than one percent (1%) of the outstanding Common Stock (after giving effect to the
conversion into Common Stock of all outstanding Series A Preferred Stock) enter into similar agreements. The underwriters in connection
with the IPO are intended third-party beneficiaries of this Section 5 and shall have the right, power and authority to
enforce the provisions hereof as though they were a party hereto. Each Key Holder further agrees to execute such agreements as
may be reasonably requested by the underwriters in the IPO that are consistent with this Section 5 or that are necessary to give
further effect thereto.

 

5.2
Stop Transfer Instructions. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions
with respect to the shares of Capital Stock of each Key Holder (and transferees and assignees thereof) until the end of such restricted
period. 

 

6.
Miscellaneous. 

 

6.1
Term. This Agreement shall automatically terminate upon the earlier of (a) immediately prior to the consummation of the
Company’s IPO; and (b) the consummation of a Deemed Liquidation Event (as defined in the Restated Certificate). 

6.2
Stock Split. All references to numbers of shares in this Agreement shall be appropriately adjusted to reflect any stock
dividend, split, combination or other recapitalization affecting the Capital Stock occurring after the date of this Agreement. 

 

6.3
Ownership. Each Key Holder represents and warrants that such Key Holder is the sole legal and beneficial owner of the shares
of Transfer Stock subject to this Agreement and that no other person or entity has any interest in such shares (other than a community
property interest as to which the holder thereof has acknowledged and agreed in writing to the restrictions and obligations hereunder). 

 

    	 

    	 

    

 

6.4
Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts
of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit,
action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding
arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the
District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such
suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its
property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum,
that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced
in or by such court. 

 

Waiver
of Jury Trial: EACH PARTY HEREBY WAIVES ITS RIGHTS
TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS,
THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND
ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION,
CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS
SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH
PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT
SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

6.5
Notices. All
notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic
mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying
next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at
their address as set forth on Schedule A or Schedule B hereof, as the case may be, or to such email address, facsimile
number or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given
to the Company, it shall be sent to Anebulo Pharmaceuticals, Inc., c/o JFL Capital Management. Ranch Road 620 South, Suite
201, Lakeway, Texas 78734, Attention: Joseph F. Lawler; and a copy (which shall not constitute notice) shall also be sent
to Faber Dauefer & Itrato PC, 890 Winter Street, Suite 315, Waltham, MA 02451.

 

(a)
Consent to Electronic Notice. Each Investor and Key Holder consents to the delivery of any stockholder notice pursuant
to the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission
pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address or the facsimile number set forth
below such Investor’s or Key Holder’s name on the Schedules hereto, as updated from time to time by notice to the
Company, or as on the books of the Company. To the extent that any notice given by means of electronic transmission is returned
or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic
mail address has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have been given. Each
Investor and Key Holder agrees to promptly notify the Company of any change in its electronic mail address, and that failure to
do so shall not affect the foregoing.

 

    	 

    	 

    

 

6.6
Entire Agreement. This Agreement (including, the Exhibits and Schedules hereto) constitutes the full and entire understanding
and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating
to the subject matter hereof existing between the parties are expressly canceled. 

 

6.7
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching
or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind
or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of
any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set
forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative. 

 

6.8
Amendment; Waiver and Termination. This Agreement may be amended, modified or terminated (other than pursuant to Section
6.1 above) and the observance of any term hereof may be waived (either generally or in a particular instance and either retroactively
or prospectively) only by a written instrument executed by (a) the Company, (b) the Key Holders then providing services to the
Company as an officer, director, consultant or employee holding a majority of the shares of Transfer Stock then held by all of
the Key Holders then providing services to the Company as an officer, director, consultant or employee, and (c) the holders of
a majority of the shares of Common Stock issued or issuable upon conversion of the then outstanding shares of Preferred Stock
held by the Investors (voting as a single separate class and on an as-converted basis and excluding any shares of Common Stock
issued pursuant to a Special Mandatory Conversion). Any amendment, modification, termination or waiver so effected shall be binding
upon the Company, the Investors, the Key Holders and all of their respective successors and permitted assigns whether or not such
party, assignee or other shareholder entered into or approved such amendment, modification, termination or waiver. Notwithstanding
the foregoing, (i) this Agreement may not be amended, modified or terminated and the observance of any term hereunder may not
be waived with respect to any Investor or Key Holder without the written consent of such Investor or Key Holder unless such amendment,
modification, termination or waiver applies to all Investors and Key Holders, respectively, in the same fashion, (ii) this Agreement
may not be amended, modified or terminated and the observance of any term hereunder may not be waived with respect to any Investor
without the written consent of such Investor, if such amendment, modification, termination or waiver would adversely affect the
rights of such Investor in a manner disproportionate to any adverse effect such amendment, modification, termination or waiver
would have on the rights of the other Investors under this Agreement, (iii) the consent of the Key Holders shall not be required
for any amendment, modification, termination or waiver if such amendment, modification, termination or waiver does not apply to
the Key Holders, and (iv) Schedule A hereto may be amended by the Company from time to time in accordance with the Purchase Agreement
to add information regarding Additional Purchasers (as defined in the Purchase Agreement) without the consent of the other parties
hereto. The Company shall give prompt written notice of any amendment, modification or termination hereof or waiver hereunder
to any party hereto that did not consent in writing to such amendment, modification, termination or waiver. No waivers of or exceptions
to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a
further or continuing waiver of any such term, condition or provision. 

    	 

    	 

    

 

6.9
Assignment of Rights. 

 

(a)
The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted
assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and permitted assigns any rights, remedies, obligations, or liabilities under or by reason
of this Agreement, except as expressly provided in this Agreement.

 

(b)
Any successor or permitted assignee of any Key Holder, including any Prospective Transferee who purchases shares of Transfer Stock
in accordance with the terms hereof, shall deliver to the Company and the Investors, as a condition to any transfer or assignment,
a counterpart signature page hereto pursuant to which such successor or permitted assignee shall confirm their agreement to be
subject to and bound by all of the provisions set forth in this Agreement that were applicable to the predecessor or assignor
of such successor or permitted assignee.

 

(c)
The rights of the Investors hereunder are not assignable without the Company’s written consent (which shall not be unreasonably
withheld, delayed or conditioned), except (i) by an Investor to any Affiliate, or (ii) to an assignee or transferee who acquires
at least 125,000 shares of Capital Stock (as adjusted for any stock combination, stock split, stock dividend, recapitalization
or other similar transaction), it being acknowledged and agreed that any such assignment, including an assignment contemplated
by the preceding clauses (i) or (ii) shall be subject to and conditioned upon any such assignee’s delivery to the Company
and the other Investors of a counterpart signature page hereto pursuant to which such assignee shall confirm their agreement to
be subject to and bound by all of the provisions set forth in this Agreement that were applicable to the assignor of such assignee.

 

(d)
Except in connection with an assignment by the Company by operation of law to the acquirer of the Company, the rights and obligations
of the Company hereunder may not be assigned under any circumstances.

 

6.10
Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability
of any other provision. 

 

6.11
Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares
of the Company’s Series A Preferred Stock after the date hereof, any purchaser of such shares of Series A Preferred Stock
may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and
thereafter shall be deemed an “Investor” for all purposes hereunder.

 

6.12
Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict
of law principles that would result in the application of any law other than the law of the State of Delaware. 

 

6.13
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. 

 

6.14
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic
mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes. 

 

    	 

    	 

    

 

6.15
Aggregation of Stock. All shares of Capital Stock held or acquired by Affiliated entities or persons shall be aggregated
together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion
such rights as among themselves in any manner they deem appropriate. 

 

6.16
Specific Performance. In addition to any and all other remedies that may be available at law in the event of any breach
of this Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company and
the Key Holders hereunder and to such other injunction or other equitable relief as may be granted by a court of competent jurisdiction. 

 

6.17
Additional Key Holders. In the event that after the date of this Agreement, the Company issues shares of Common Stock,
or options to purchase Common Stock, to any employee or consultant, which shares or options would collectively constitute with
respect to such employee or consultant (taking into account all shares of Common Stock, options and other purchase rights held
by such employee or consultant) one percent (1%) or more of the Company’s then outstanding Common Stock (treating for this
purpose all shares of Common Stock issuable upon exercise of or conversion of outstanding options, warrants or convertible securities,
as if exercised or converted), the Company shall, as a condition to such issuance, cause such employee or consultant to execute
a counterpart signature page hereto as a Key Holder, and such person shall thereby be bound by, and subject to, all the terms
and provisions of this Agreement applicable to a Key Holder. 

 

[Remainder
of Page Intentionally Left Blank]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Right of First Refusal and Co-Sale Agreement as of the date first written above.

 

	 	ANEBULO
    PHARMACEUTICALS, INC.
	 	 
	 	By:	 
	 	Name:	Joseph
    F. Lawler
	 	Title:	President
	 	 	 
	 	KEY
    HOLDERS:
	 	 
	 	Signature:	 
	 	Name:
    	Joseph
    F. Lawler
	 	 	 
	 	INVESTOR:
	 	 
	 	22NW,
    LP
	 	 
	 	By:	 
	 	Name:
    	Aron
    English
	 	Title:	President

 

    	 

    	 

    

 

SCHEDULE
A

INVESTORS

 

	Name
    and Address	 	Number
    of Shares Held
	 	 	 
	22NW,
    LP	 	341,250
	1455
    NW Leary Way, Suite 400	 	 
	Seattle,
    WA 98107	 	 

 

    	 

    	 

    

 

SCHEDULE
B

KEY HOLDERS

 

	Name
    and Address	 	Number
    of Shares Held
	 	 	 
	
        Joseph F. Lawler

         

        c/o JFL Capital Management

        1415 Ranch Road 620 South,

        Suite 201

        Lakeway, Texas 78734 
	 	
        2,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]